Immix Biopharma, Inc.
IMMX
$4.15
$0.184.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 12.14% | 1.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.06% | 43.45% | |||
| Operating Income | -14.06% | -43.45% | |||
| Income Before Tax | -14.58% | -45.91% | |||
| Income Tax Expenses | -13.48% | -9.18% | |||
| Earnings from Continuing Operations | -14.54% | -45.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -14.54% | -45.79% | |||
| EBIT | -14.06% | -43.45% | |||
| EBITDA | -13.61% | -43.37% | |||
| EPS Basic | -7.56% | -44.47% | |||
| Normalized Basic EPS | -7.54% | -44.55% | |||
| EPS Diluted | -7.56% | -44.47% | |||
| Normalized Diluted EPS | -7.54% | -44.55% | |||
| Average Basic Shares Outstanding | 6.48% | 0.95% | |||
| Average Diluted Shares Outstanding | 6.48% | 0.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||